Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nuciferine
- Development stage
- Preclinical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Nuciferine is a naturally occurring aporphine alkaloid primarily found in the leaves of Nelumbo nucifera (sacred lotus) and Nymphaea caerulea. It has been traditionally used in herbal medicine and is a major phytochemical constituent of lotus leaf extracts. Pharmacologically, nuciferine exhibits a receptor profile similar to atypical antipsychotics and demonstrates antipsychotic-like effects in animal models without inducing catalepsy. Its mechanisms include antagonism at serotonin 5-HT2A/2B/2C receptors; inverse agonism at 5-HT7; partial agonism at dopamine D2/D5 and serotonin 5-HT6 receptors; agonism at dopamine D4 and serotonin 5-HT1A receptors; as well as inhibition of the dopamine transporter (DAT). Beyond CNS activity, it has reported anti-obesity, anti-dyslipidemia, anti-hyperglycemic, anti-inflammatory, antioxidant, antimicrobial and potential anticancer effects. The compound modulates metabolic pathways related to obesity and inflammation—possibly via PPAR delta activation—and influences gut microbiota composition[1][2][3][4][5].
- Other names
- NuciferinSanjoinine El-Nuciferine(-)-nuciferine
02
Targets
HTR6 (5-hydroxytryptamine receptor 6)DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR7 (5-hydroxytryptamine receptor 7)DRD5 (Dopamine D5 Receptor)HTR2C (5-hydroxytryptamine 2C receptor)DAT (Dopamine plasma membrane transport protein)PPARD (Peroxisome proliferator–activated receptor delta)DRD2 (Dopamine D2 Receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on nuciferine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nuciferine.